Adverse effects of low-dose glucocorticoids and DMARD therapy in patients with RA - A complex relationship?

John Kirwan*

*Corresponding author for this work

    Research output: Contribution to journalArticle (Academic Journal)peer-review

    2 Citations (Scopus)


    Although low-dose glucocorticoids, in conjunction with DMARDs, are known to halt or severely retard the erosive destruction of joints in patients with early rheumatoid arthritis (RA), the potential adverse effects of low-dose glucocorticoids and the benefit:risk ratio of treatment are a concern for many clinicians. Malysheva and colleagues undertook a retrospective, open-label review of the incidence and severity of adverse effects associated with DMARD treatment with or without glucocorticoids in patients with RA. Their results suggest that low-dose glucocorticoids actually help to postpone the occurrence of adverse effects caused by most standard DMARDs, which, if translated into a delay before biologic agents were required, would provide a substantial cost saving. Unfortunately, an increased incidence of adverse reactions was noted for glucocorticoid-treated patients compared with those patients on monotherapy; however, the undesirable effects were mostly mild in nature. This study sheds new light on the relative risks and benefits of low-dose glucocorticoid therapy in RA and adds further weight to the arguments for its appropriate use in early disease.

    Original languageEnglish
    Pages (from-to)568-569
    Number of pages2
    JournalNature Clinical Practice Rheumatology
    Issue number11
    Publication statusPublished - 10 Sep 2008

    Fingerprint Dive into the research topics of 'Adverse effects of low-dose glucocorticoids and DMARD therapy in patients with RA - A complex relationship?'. Together they form a unique fingerprint.

    Cite this